Herman F Staats

List of Publications by Year
in descending order

89 papers	4,289 citations	126907 33 h-index	114465 63 g-index
91 all docs	91 docs citations	91 times ranked	5019 citing authors

#	Article	IF	Citations
1	Highly-loaded protein nanocarriers prepared by Flash NanoPrecipitation with hydrophobic ion pairing. International Journal of Pharmaceutics, 2021, 601, 120397.	5.2	7
2	Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits (Oryctolagus cuniculus). Journal of Visualized Experiments, 2021, , .	0.3	2
3	Nasal Immunization With Small Molecule Mast Cell Activators Enhance Immunity to Co-Administered Subunit Immunogens. Frontiers in Immunology, 2021, 12, 730346.	4.8	9
4	Innate Immunity-Based Mucosal Modulators and Adjuvants. , 2020, , 167-183.		5
5	Mast Cells for the Control of Mucosal Immunity. , 2020, , 213-228.		1
6	Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy. Npj Vaccines, 2020, 5, 12.	6.0	21
7	Fecal IgA, Antigen Absorption, and Gut Microbiome Composition Are Associated With Food Antigen Sensitization in Genetically Susceptible Mice. Frontiers in Immunology, 2020, 11, 599637.	4.8	20
8	Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen. Journal of Virology, 2019, 93, .	3.4	9
9	Identification of Novel Mast Cell Activators Using Cell-Based High-Throughput Screening. SLAS Discovery, 2019, 24, 628-640.	2.7	7
10	Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. Journal of Virology, 2019, 93, .	3.4	37
11	Nasal peanut+ CpG immunotherapy enhances peanutâ€specific <scp>IFN</scp>â€Î³ in Th2 cells and <scp>IL</scp>â€10 in nonâ€Th2 cells in mice. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2220-2223.	5.7	12
12	MRGPR-mediated activation of local mast cells clears cutaneous bacterial infection and protects against reinfection. Science Advances, 2019, 5, eaav0216.	10.3	78
13	Effect of endotoxin and alum adjuvant vaccine on peanut allergy. Journal of Allergy and Clinical Immunology, 2018, 141, 791-794.e8.	2.9	6
14	Perivascular dendritic cells elicit anaphylaxis by relaying allergens to mast cells via microvesicles. Science, 2018, 362, .	12.6	56
15	Adjuvanted Immunotherapy Approaches for Peanut Allergy. Frontiers in Immunology, 2018, 9, 2156.	4.8	10
16	Mast cell activators as novel immune regulators. Current Opinion in Pharmacology, 2018, 41, 89-95.	3.5	23
17	Assessing the satisfaction and burden within an academic animal care and use program. FASEB Journal, 2017, 31, 3913-3921.	0.5	7
18	Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge. Vaccine Journal, 2016, 23, 648-651.	3.1	4

#	Article	IF	Citations
19	Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or imiquimod generates a persistent humoral immune response that recognizes the bacterial surface. Vaccine, 2016, 34, 1193-1200.	3.8	12
20	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. Journal of Virology, 2016, 90, 4951-4965.	3.4	23
21	Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Journal of Controlled Release, 2015, 213, e66-e67.	9.9	2
22	Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers. Vaccine, 2015, 33, 4141-4145.	3.8	11
23	Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination. Vaccine, 2015, 33, 3609-3613.	3.8	22
24	Nasal Dry Powder Vaccine Delivery Technology. , 2014, , 717-726.		1
25	Scale of Health: Indices of Safety and Efficacy in the Evolving Environment of Large Biological Datasets. Pharmaceutical Research, 2014, 31, 2256-2265.	3.5	4
26	Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Scientific Reports, 2014, 4, 5128.	3.3	94
27	Which comes first: the antigen or the adjuvant?. Journal of Clinical Investigation, 2014, 124, 2364-2365.	8.2	1
28	A mast cell degranulation screening assay for the identification of novel mast cell activating agents. MedChemComm, 2013, 4, 88-94.	3.4	15
29	A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses. Peptides, 2013, 48, 96-105.	2.4	46
30	Evaluation of vaccine-induced antibody responses: Impact of new technologies. Vaccine, 2013, 31, 2756-2761.	3.8	18
31	Salmonella Typhimurium Impedes Innate Immunity with a Mast-Cell-Suppressing Protein Tyrosine Phosphatase, SptP. Immunity, 2013, 39, 1108-1120.	14.3	52
32	Genomic correlates of variability in immune response to an oral cholera vaccine. European Journal of Human Genetics, 2013, 21, 1000-1006.	2.8	9
33	A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen. Vaccine, 2013, 31, 1480-1489.	3.8	27
34	Mucosal Immunization of Lactating Female Rhesus Monkeys with a Transmitted/Founder HIV-1 Envelope Induces Strong Env-Specific IgA Antibody Responses in Breast Milk. Journal of Virology, 2013, 87, 6986-6999.	3.4	38
35	Maximal Adjuvant Activity of Nasally Delivered IL-1Î± Requires Adjuvant-Responsive CD11c+ Cells and Does Not Correlate with Adjuvant-Induced In Vivo Cytokine Production. Journal of Immunology, 2012, 188, 2834-2846.	0.8	23
36	Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nature Materials, 2012, 11, 250-257.	27.5	89

#	Article	IF	Citations
37	Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy. Journal of Allergy and Clinical Immunology, 2012, 129, 1159-1162.	2.9	89
38	Stable Dry Powder Formulation for Nasal Delivery of Anthrax Vaccine. Journal of Pharmaceutical Sciences, 2012, 101, 31-47.	3.3	82
39	Dry Powder Vaccines for Mucosal Administration: Critical Factors in Manufacture and Delivery. Current Topics in Microbiology and Immunology, 2011, 354, 121-156.	1.1	15
40	Scarcity or Absence of Humoral Immune Responses in the Plasma and Cervicovaginal Lavage Fluids of Heavily HIV-1-Exposed But Persistently Seronegative Women. AIDS Research and Human Retroviruses, 2011, 27, 469-486.	1.1	46
41	Cytokines: The Future of Intranasal Vaccine Adjuvants. Clinical and Developmental Immunology, 2011, 2011, 1-17.	3.3	52
42	Mucosal Targeting of a BoNT/A Subunit Vaccine Adjuvanted with a Mast Cell Activator Enhances Induction of BoNT/A Neutralizing Antibodies in Rabbits. PLoS ONE, 2011, 6, e16532.	2.5	36
43	Adenovirus F protein as a delivery vehicle for botulinum B. BMC Immunology, 2010, 11, 36.	2.2	7
44	Chaperoning vaccines. Nature Materials, 2010, 9, 537-538.	27.5	9
45	Immunization with the Haemophilus ducreyi Hemoglobin Receptor HgbA with Adjuvant Monophosphoryl Lipid A Protects Swine from a Homologous but Not a Heterologous Challenge. Infection and Immunity, 2010, 78, 3763-3772.	2.2	21
46	Development of a Bead Immunoassay To Measure Vi Polysaccharide-Specific Serum IgG after Vaccination with the Salmonella enterica Serovar Typhi Vi Polysaccharide. Vaccine Journal, 2010, 17, 412-419.	3.1	10
47	Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1. Vaccine, 2010, 28, 6901-6914.	3.8	34
48	Mast cellâ€“derived particles deliver peripheral signals to remote lymph nodes. Journal of Experimental Medicine, 2009, 206, 2455-2467.	8.5	151
49	Identification of recombinant antibodies against multiple distinct toll-like receptors by homolog mining a single immune scFv phage library. Journal of Immunological Methods, 2009, 340, 144-153.	1.4	6
50	Genetic determinants of immune-response to a polysaccharide vaccine for typhoid. The HUGO Journal, 2009, 3, 17-30.	4.1	13
51	Mast Cells Augment Adaptive Immunity by Orchestrating Dendritic Cell Trafficking through Infected Tissues. Cell Host and Microbe, 2009, 6, 331-342.	11.0	113
52	The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine, 2009, 27, 3544-3552.	3.8	72
53	Mast cell activators: a new class of highly effective vaccine adjuvants. Nature Medicine, 2008, 14, 536-541.	30.7	192
54	An Entirely Cell-Based System to Generate Single-Chain Antibodies against Cell Surface Receptors. Journal of Molecular Biology, 2008, 379, 261-272.	4.2	30

#	Article	IF	Citations
55	Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. Vaccine, 2008, 26, 4267-4275.	3.8	33
56	The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine, 2008, 26, 4998-5003.	3.8	21
57	Nonmucosal Alphavirus Vaccination Stimulates a Mucosal Inductive Environment in the Peripheral Draining Lymph Node. Journal of Immunology, 2008, 181, 574-585.	0.8	25
58	In Vitro and In Vivo Characterization of Anthrax Anti-Protective Antigen and Anti-Lethal Factor Monoclonal Antibodies after Passive Transfer in a Mouse Lethal Toxin Challenge Model To Define Correlates of Immunity. Infection and Immunity, 2007, 75, 5443-5452.	2.2	55
59	Mucosal vaccine development for botulinum intoxication. Expert Review of Vaccines, 2007, 6, 35-45.	4.4	13
60	Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS PharmSciTech, 2007, 8, 2-10.	3.3	114
61	Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3722-3727.	7.1	90
62	Oral immunogenicity of the plant proteinase bromelain. International Immunopharmacology, 2006, 6, 2038-2046.	3.8	22
63	Mucosal Vaccine Targeting Improves Onset of Mucosal and Systemic Immunity to Botulinum Neurotoxin A. Journal of Immunology, 2006, 177, 5524-5532.	0.8	26
64	Capric Acid and Hydroxypropylmethylcellulose Increase the Immunogenicity of Nasally Administered Peptide Vaccines. AIDS Research and Human Retroviruses, 2006, 22, 558-568.	1.1	16
65	Generation of Mucosal Anti-Human Immunodeficiency Virus Type 1 T-Cell Responses by Recombinant Mycobacterium smegmatisâ–¿. Vaccine Journal, 2006, 13, 1204-1211.	3.1	20
66	Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies. Science, 2005, 308, 1906-1908.	12.6	704
67	A Novel Neurotoxoid Vaccine Prevents Mucosal Botulism. Journal of Immunology, 2005, 174, 2190-2195.	0.8	32
68	Gender Differences in Human Immunodeficiency Virus Type 1-Specific CD8 Responses in the Reproductive Tract and Colon following Nasal Peptide Priming and Modified Vaccinia Virus Ankara Boosting. Journal of Virology, 2004, 78, 13163-13172.	3.4	17
69	Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8+ T cell population in different tissues. Vaccine, 2004, 22, 1390-1394.	3.8	14
70	A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine, 2004, 22, 3774-3788.	3.8	58
71	Mast cellâ€“derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nature Immunology, 2003, 4, 1199-1205.	14.5	290
72	Prolonged CD4+Cell/Virus Load Discordance during Treatment with Protease Inhibitorâ€“Based Highly Active Antiretroviral Therapy: Immune Response and Viral Control. Journal of Infectious Diseases, 2003, 187, 1027-1037.	4.0	71

#	Article	IF	Citations
73	Detection of Mucosal Antibodies in HIV Type 1-Infected Individuals. AIDS Research and Human Retroviruses, 2002, 18, 1291-1300.	1.1	72
74	Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization. Journal of Virology, 2002, 76, 517-524.	3.4	91
75	HIV Mucosal Vaccines. , 2002, , 165-190.		0
76	Increased immunogenicity of HIV envelope subunit complexed with Î±2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF. Vaccine, 2002, 20, 2396-2403.	3.8	18
77	Cytokine Requirements for Induction of Systemic and Mucosal CTL After Nasal Immunization. Journal of Immunology, 2001, 167, 5386-5394.	0.8	90
78	HIV Vaccine Development at Duke University Medical Center. Immunologic Research, 2000, 22, 263-270.	2.9	0
79	Human Nasopharyngeal-Associated Lymphoreticular Tissues. American Journal of Pathology, 2000, 157, 2023-2035.	3.8	85
80	Intranasal Immunization with Cytotoxic T-Lymphocyte Epitope Peptide and Mucosal Adjuvant Cholera Toxin: Selective Augmentation of Peptide-Presenting Dendritic Cells in Nasal Mucosa-Associated Lymphoid Tissue. Infection and Immunity, 1998, 66, 5876-5881.	2.2	58
81	Intranasal Immunization Is Superior to Vaginal, Gastric, or Rectal Immunization for the Induction of Systemic and Mucosal Anti-HIV Antibody Responses. AIDS Research and Human Retroviruses, 1997, 13, 945-952.	1.1	102
82	The V3 Domain of SIVmac251 gp120 Contains a Linear Neutralizing Epitope. Virology, 1996, 224, 415-426.	2.4	17
83	Mucosal Immunity in HIV Infection. , 1996, , 387-416.		2
84	Vaccines for Selective Induction of Th1- and Th2-Cell Responses and Their Roles in Mucosal Immunity. , 1996, , 461-475.		4
85	Application of Basic Principles of Mucosal Immunity to Vaccine Development. , 1996, , 17-39.		16
86	Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxin. Immunopharmacology, 1995, 31, 31-41.	2.0	1
87	Mucosal immunity to infection with implications for vaccine development. Current Opinion in Immunology, 1994, 6, 572-583.	5.5	194
88	Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine, 1994, 12, 903-911.	3.8	117
89	Effective Antibody Therapy in Herpes Simplex Virus Ocular Infection. Intervirology, 1990, 31, 159-165.	2.8	21